--------------------------------------------------------------------------------

FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

Acne

Avita Gel (by Penederm), Approved January 1997
Treatment for acne

Benzamycin (erythromycin 3%-benzoyl peroxide 5% topical gel) (by Dermik Laboratories), Approved November 2000
For the topical treatment of acne vulgaris

Clindamycin phosphate topical gel (by Target Research Associates), Approved November 2000
For once a day treatment of acne vulgaris

Clindamycin Phosphate Topical Solution USP 1% (by Morton Grove Pharmaceuticals), Approved July 1997
Generic equivalent of CLEOCIN Topical Solution 1%

Differin (adapalene gel) Gel, 0.1% (by Galderma Laboratories), Approved June 1996
Treatment for acne

Estrostep (norethindrone acetate and ethinyl estradiol) (by Pfizer), Approved July 2001
For the treatment of moderate acne vulgaris

Finevin (by Berlex Laboratories), Approved May 2001
Topical cream for the treatment of mild to moderate inflammatory acne vulgaris

Klaron (sodium sulfacet amide lotion ) Lotion, 10% (by Dermik Laboratories), Approved February 1997
Treatment for adult acne

Ortho Tri-Cyclen Tablets (norgestimate/ethinyl estradiol) (by Ortho-McNeil Pharmaceutical), Approved January 1997
Treatment for acne in women seeking contraception

Retin-A Micro (tretinoin gel) microsphere, 0.1% (by Advanced Polymer Systems), Approved February 1997
Treatment for acne

Tazorac topical gel (by Allergan), Approved June 1997
Treatment for Psoriasis, Acne Vulgaris

Veltin (clindamycin phosphate and tretinoin) (by Stiefel), Approved July 2010
For the treatment of acne vulgaris

Acromegaly

Signifor LAR (pasireotide) (by Novartis), Approved December 2014
For the treatment of acromegaly

Acute Myelogenous Leukemia (AML)

Mylotarg (gemtuzumab ozogamicin) (by Wyeth), Approved May 2000
For the treatment of CD33 positive acute myeloid leukemia (AML)

Acute Myeloid Leukemia

IDHIFA (enasidenib) (by Celgene), Approved August 2017
For the treatment of relapsed or refractory acute myeloid leukemia with IDH2 mutation

Vyxeos (daunorubicin and cytarabine) (by Jazz Pharma), Approved August 2017
For the treatment of newly-diagnosed therapy-related AML or AML with myelodysplasia-related changes

Acute Pain

Belbuca (buprenorphine) (by Endo Pharmaceuticals), Approved October 2015
For the management of severe pain

Exparel (bupivacaine liposome injectable suspension) (by Pacira Pharmaceuticals), Approved November 2011
For postsurgical analgesia

Omidria (phenylephrine and ketorolac injection) (by Omeros), Approved June 2014
For use during eye surgery to prevent intraoperative miosis and reduce post-operative pain

Tivorbex (indomethacin) (by Iroko Pharmaceuticals), Approved February of 2014
For the treatment of acute pain

Troxyca ER (oxycodone + naltrexone) (by Pfizer), Approved August 2016
For the management of severe pain

Vivlodex (meloxicam) (by Iroko Pharmaceuticals), Approved October 2015
For the management of osteoarthritis pain

Xartemis XR (oxycodone hydrochloride and acetaminophen) extended release (by Mallinckrodt Pharmaceuticals), Approved March 2014
For the management of acute pain

Zingo (lidocaine hydrochloride monohydrate) (by Powder Pharmaceuticals), Approved August 2007
For local analgesia prior to venipuncture or peripheral intravenous cannulation

Addictions

Bunavail (buprenorphine and naloxone) (by BioDelivery Sciences), Approved June 2014
For the maintenance treatment of opioid dependence

Vivitrol (naltrexone for extended-release injectable suspension) (by Alkermes), Approved October 2010
For the prevention of relapse to opioid dependence

Zubsolv (buprenorphine and naloxone) (by Orexo AB), Approved July 2013
For the maintenance treatment of opioid dependence

Adverse Effects, Drugs

Bunavail (buprenorphine and naloxone) (by BioDelivery Sciences), Approved June 2014
For the maintenance treatment of opioid dependence

Kcentra (Prothrombin Complex Concentrate) (by CSL Behring), Approved May 2013
For the reversal of vitamin K antagonist therapy-induced coagulation factor deficiency

Movantik (naloxegol) (by AstraZeneca), Approved September 2014
For the treatment of opiod-induced constipation in adults with chronic non-cancer pain

Myalept (metreleptin for injection) (by Bristol-Myers Squibb), Approved February of 2014
For the treatment of congenital or acquired generalized lipodystrophy

Neutroval (tbo-filgrastim) (by Teva Pharmaceutical), Approved August 2012
For the reduction in the duration of severe chemotherapy-induced neutropenia

Praxbind (idarucizumab) (by Boehringer Ingelheim), Approved October 2015
For the reversal of the anticoagulant effects of dabigatran

Sustol (granisetron) (by Heron Therapeutics), Approved August 2016
For the prevention of chemotherapy-induced nausea and vomiting

Symproic (naldemedine) (by Shionogi), Approved March 2017
For the treatment of opioid-induced constipation

Vistogard (uridine triacetate) (by Wellstat Therapeutics), Approved December 2015
For the emergency treatment of patients with a fluorouracil or capecitabine overdose

Voraxaze (glucarpidase) (by BTG International), Approved January 2012
For the treatment of toxic plasma methotrexate concentrations in patients with impaired renal function

AIDS and AIDS related infections

Clarithromycin (Biaxin) (by Abbott Laboratories), Approved December 1995
Treatment for the prevention of disseminated Mycobacterium avium complex (MAC)

Syndros (dronabinol oral solution) (by Insys Therapeutics), Approved July 2016
For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy

Valcyte (valganciclovir HCl) (by Roche), Approved March 2001
For the treatment of cytomegalovirus retinitis in patients with AIDS

Alcohol Dependence

Campral (acamprosate calcium) (by Forest Laboratories), Approved August, 2004
For the treatment of alcohol dependence and the maintenance of alcohol abstinence

Naltrexone Hydrochloride Tablets (by Barr Laboratories), Approved May 1998
Generic equivalent of Revia

Vivitrol (naltrexone for extended-release injectable suspension) (by Alkermes), Approved April 2006
For the treatment of alcohol dependence

Allergies & Asthma

Dymista (azelastine hydrochloride and fluticasone propionate) (by Meda Pharmaceuticals Inc), Approved May 2012
For the relief of symptoms of seasonal allergic rhinitis

Grastek (Timothy Grass Pollen Allergen Extract) (by Merck), Approved April 2014
For the treatment of grass pollen-induced allergic rhinitis

Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) (by Greer Labs), Approved April 2014
For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis

Qnasl (beclomethasone dipropionate) nasal aerosol (by Teva Pharmaceutical), Approved March 2012
For the treatment of seasonal and perennial allergic rhinitis

Ragwitek (Short Ragweed Pollen Allergen Extract) (by Merck), Approved April 2014
For the treatment of short ragweed pollen-induced allergic rhinitis

Allergy

AK-Con-A (naphazoline ophthalmic) (by Akorn), Approved January 1996
Over-the-counter combination vasoconstrictor/antihistamine product for opthalmic use

Allegra (fexofenadine hydrochloride) (by Hoechst Marion Roussel), Approved July 1996
Treatment for seasonal allergy symptoms

Allegra-D (by Hoechst Marion Roussel), Approved March 1998
Treatment for nasal congestion due to seasonal allergy

Astelin nasal spray (by Wallace Laboratories), Approved November 1996
Treatment for seasonal allergic rhinitis

Astepro (azelastine hydrochloride nasal spray) (by Meda Pharmaceuticals Inc), Approved October 2008
For the treatment of seasonal and perennial allergic rhinitis

Atrovent (ipratropium bromide) (by Boehringer Ingelheim), Approved January 1996
Treatment for runny nose due to allergies and the common cold

Clarinex (by Schering-Plough), Approved February 2002
Once-daily oral tablet for the treatment of allergic rhinitis and chronic ideopathic urticaria

Claritin RediTabs (10 mg loratadine rapidly-disintegrating tablet) (by Schering-Plough), Approved January 1997
Treatment for seasonal allergy symptoms

Clemastine fumarate syrup (by Morton Grove Pharmaceuticals), Approved March 1998
Generic equivalent of Tavist Syrup

Dymista (azelastine hydrochloride and fluticasone propionate) (by Meda Pharmaceuticals Inc), Approved May 2012
For the relief of symptoms of seasonal allergic rhinitis

Flonase Nasal Spray (by GlaxoSmithKline), Approved November 1997
Treatment for seasonal and perennial allergic rhinitis

Grastek (Timothy Grass Pollen Allergen Extract) (by Merck), Approved April 2014
For the treatment of grass pollen-induced allergic rhinitis

IvyBlock (by EnviroDerm Pharmaceuticals), Approved September 1996
Treatment for poison ivy, poison oak, and poison sumac

Nasacort AQ (triamcinolone acetonide) Nasal Spray (by Rhone Poulenc Rorer), Approved May 1996
Treatment for allergic rhinitis

NasalCrom Nasal Spray (by Pharmacia & Upjohn), Approved April 2001
Over-the-counter nasal spray for treatment of all nasal allergy symptoms

Nasonex Nasal Spray (by Schering-Plough), Approved January 1999
Treatment of seasonal allergic rhinitis

Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) (by Greer Labs), Approved April 2014
For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis

Patanase (olopatadine hydrochloride) (by Alcon), Approved April 2008
For the treatment of seasonal allergic rhinitis

Qnasl (beclomethasone dipropionate) nasal aerosol (by Teva Pharmaceutical), Approved March 2012
For the treatment of seasonal and perennial allergic rhinitis

Ragwitek (Short Ragweed Pollen Allergen Extract) (by Merck), Approved April 2014
For the treatment of short ragweed pollen-induced allergic rhinitis

Rhinocort Aqua Nasal Spray (by AstraZeneca), Approved October 1999
A nasal spray containing budesonide

Tavist (clemastine fumarate) (by Novartis), Approved March 2001
Oral tablet for temporary relief of symptoms associated with hay fever, allergic rhinitis, and the common cold

Tri-Nasal Spray (triamcinolone acetonide spray) (by Muro Pharmaceutical), Approved February 2000
For treatment of nasal symptoms of allergic rhinitis in adults and children age 12 or older

Vancenase AQ 84 mcg Double Strength (by Schering-Plough), Approved June 1996
Treatment for allergic and non-allergic rhinitis

Veramyst (fluticasone furoate) (by GlaxoSmithKline), Approved April 2007
For the treatment of seasonal and perennial allergic rhinitis

Xyzal (levocetirizine dihydrochloride) (by UCB), Approved May 2007
For the treatment of seasonal and perennial allergic rhinitis and urticaria

Zerviate (cetirizine ophthalmic solution 0.24%) (by NicOx), Approved May 2017
For the treatment of ocular itching associated with allergic conjunctivitis

Zyrtec (cetirizine HCl) (by Pfizer), Approved December 1995
Treatment for year-round allergies, seasonal allergic rhinitis, and chronic itching and hives

Allergy (Pediatric)

Claritin Syrup (loratadine) (by Schering-Plough), Approved October 1996
Treatment for children with seasonal allergies

Qnasl (beclomethasone dipropionate) nasal aerosol (by Teva Pharmaceutical), Approved March 2012
For the treatment of seasonal and perennial allergic rhinitis

Alzheimer's Disease

ARICEPT (donepezil hydrochloride) (by Eisai), Approved December 1996
Treatment for Alzheimer's Disease

Exelon (rivastigmine tartrate) (by Novartis), Approved April 2000
Indicated for the treatment of mild to moderate dementia of the Alzheimer's type

Exelon (rivastigmine tartrate) (by Novartis), Approved July 2007
For the treatment of Alzheimer's and Parkinson's disease-related dementia

Femstat 3 (butoconazole nitrate 2%) (by Procter & Gamble, Roche), Approved December 1995
Over the counter treatment for vaginal yeast infections

Namenda (memantine HCl) (by Forest Laboratories), Approved October 2003
For the treatment of moderate to severe dementia of the Alzheimer’s type.

Namzaric (memantine hydrochloride extended-release + donepezil hydrochloride) (by Forest Laboratories), Approved December 2014
For the treatment of moderate to severe dementia of the Alzheimer's type

Reminyl (galantamine hydrobromide) (by Janssen Pharmaceuticals), Approved February 2001
For the treatment of mild to moderate dementia of the Alzheimer's type

Amenorrhea

Prometrium (by Solvay Pharmaceuticals), Approved May 1998
Treatment for amenorrhea (abnormal cessation of menses)

Amyotrophic Lateral Sclerosis (ALS)

Radicava (edaravone) (by Mitsubishi Tanabe Pharma), Approved May 2017
For the treatment of amyotrophic lateral sclerosis

Rilutek (riluzole) (by Rhone Poulenc Rorer), Approved December 1995
Treatment for amyotrophic lateral sclerosis (ALS)

Anal Fissures

Rectiv (nitroglycerin) ointment 0.4% (by ProStrakan), Approved June 2011
For the treatment of chronic anal fissure

Anemia

Elelyso (taliglucerase alfa) (by Pfizer), Approved May 2012
For the treatment of Gaucher disease

Ferriprox (deferiprone) (by Apotex), Approved October 2011
For the treatment of transfusional iron overload due to thalassemia

Injectafer (ferric carboxymaltose injection) (by Luitpold Pharmaceuticals), Approved July 2013
For the treatment of iron deficiency anemia

Omontys (peginesatide) (by Affymax), Approved March 2012
For the treatment of anemia due to chronic kidney disease

Venofer (iron sucrose injection) (by Luitpold Pharmaceuticals), Approved November 2000
For the treatment of iron deficiency anemia in patients undergoing chronic hemodialysis

Anesthesia (Local)

Zingo (lidocaine hydrochloride monohydrate) (by Powder Pharmaceuticals), Approved August 2007
For local analgesia prior to venipuncture or peripheral intravenous cannulation

Angina

Caduet (amlodipine/atorvastatin) (by Pfizer), Approved January 2004
For the treatment of hypertension, chronic stable angina and vasospastic angina

Nitrostat (nitroglycerin) Tablets (by Parke-Davis), Approved May 2000
For the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.

Posicor (by Roche), Approved June 1997
Treatment for hypertension and chronic stable angina pectoris

Ranexa (ranolazine) (by CV Therapeutics), Approved January 2006
For the treatment of chronic angina in patients failing first-line therapy

Tiazac (diltiazem hydrochloride) (by Forest Laboratories), Approved February 1998
Treatment for chronic stable angina

Toprol-XL (metoprolol succinate) (by AstraZeneca), Approved January 1995
For the treatment of hypertension, angina pectoris and heart failure

Ankylosing Spondylitis

Rayos (prednisone) delayed-release tablets (by Horizon Pharma), Approved July of 2012
For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions

Anorexia

Syndros (dronabinol oral solution) (by Insys Therapeutics), Approved July 2016
For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy

Arrhythmia

Procanbid (procainamide hydrochloride extended-release tablets) (by Warner-Lambert), Approved January 1996
Treatment for ventricular arrhythmias

Arthritis and Arthritic Pain

Arthrotec (by Searle), Approved December 1997
Treatment for arthritis

Lodine XL (etodolac) (by Wyeth), Approved February 1998
Treatment for arthritis

Otezla (apremilast) (by Celgene), Approved March 2014
For the treatment of adults with active psoriatic arthritis

Rayos (prednisone) delayed-release tablets (by Horizon Pharma), Approved July of 2012
For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions

Tolmetin Sodium (by Teva Pharmaceutical), Approved March 1997
Treatment for arthritis

Xeljanz (tofacitinib) (by Pfizer), Approved November 2012
For the treatment of moderately to severely active rheumatoid arthritis

Arthritis and Arthritic Pain (Pediatric)

Actemra (ocilizumab) (by Genentech), Approved May 2013
For the treatment of Polyarticular Juvenile Idiopathic Arthritis

Actemra (tocilizumab) (by Genentech), Approved April 2011
For the treatment of systemic juvenile idiopathic arthritis

Aspergillosis

Cresemba (isavuconazonium sulfate) (by Astellas), Approved March 2015
For the treatment of invasive aspergillosis and invasive mucormycosis

Asthma

Accolate (by AstraZeneca), Approved October 1996
Treatment for asthma

Advair (fluticasone propionate and salmeterol) (by GlaxoSmithKline), Approved August 2000
For the treatment of asthma and chronic obstructive pulmonary disease

Alvesco (ciclesonide) (by Nycomed), Approved January 2008
For the maintenance treatment of asthma as prophylactic therapy in adults and adolescents

Arnuity Ellipta (fluticasone furoate inhalation powder) (by GlaxoSmithKline), Approved August 2014
For the treatment of asthma

Azmacort (triamcinolone acetonide) Inhalation Aerosol (by Rhone Poulenc Rorer), Approved November 1996
Treatment for asthma

Cinqair (reslizumab) (by Teva Pharmaceuticals), Approved March 2016
For the treatment of severe asthma

Dulera (mometasone furoate + formoterol fumarate dihydrate) (by Merck), Approved June 2010
For the treatment of asthma

Flovent Rotadisk (by GlaxoSmithKline), Approved November 1997
Treatment of asthma in patients four and older

Foradil Aerolizer (formoterol fumarate inhalation powder) (by Novartis), Approved February 2001 (asthma, bronchospasm); September 2001 (COPD)
Bronchodilator for COPD, asthma and bronchospasm

Metaprotereol Sulfate Inhalation Solution, 5% (by Morton Grove Pharmaceuticals), Approved March 1997
Generic equivalent of Alupentr Inhalation Solution, 5%

Nucala (mepolizumab) (by GlaxoSmithKline), Approved November 2015
For the treatment of severe asthma with an eosinophilic phenotype

Qvar (beclomethasone dipropionate) (by Ivax), Approved May 2002
For the treatment of asthma

Rayos (prednisone) delayed-release tablets (by Horizon Pharma), Approved July of 2012
For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions

Serevent (by GlaxoSmithKline), Approved September 1997
Treatment of asthma

Singulair (by Merck), Approved February 1998
Treatment for asthma

Tilade (nedocromil sodium) (by Rhone Poulenc Rorer), Approved April 1997
Treatment for asthma

Tilade (nedocromil sodium) (by Rhone Poulenc Rorer), Approved November 1997
Treatment for mild to moderate asthma

Vanceril 84 mcg Double Strength (beclomethasone dipropionate, 84 mcg) Inhalation Aerosol (by Schering-Plough), Approved January 1997
Treatment for asthma

Ventolin HFA (albuterol sulfate inhalation aerosol) (by GlaxoSmithKline), Approved April 2001
For the treatment or prevention of bronchospasm

Xolair (omalizumab) (by Genentech), Approved June 2003
For the treatment of asthma

Zyflo (Zileuton) (by Abbott Laboratories), Approved January 1997
Treatment for asthma in patients 12 years and older

Asthma (Pediatric)

Accolate (by AstraZeneca), Approved September 1999
zafirlukast, 10 mg and 20 mg tablets.

Arnuity Ellipta (fluticasone furoate inhalation powder) (by GlaxoSmithKline), Approved August 2014
For the treatment of asthma

Tilade (nedocromil sodium) (by Rhone Poulenc Rorer), Approved April 1997
Treatment for mild-to-moderate bronchial asthma

Atherosclerosis

Lescol (fluvastatin sodium) (by Novartis), Approved September 1997
Treatment for coronary atherosclerosis

Plavix (clopidogrel bisulfate) (by Sanofi-aventis, Bristol-Myers Squibb), Approved November 1997
Treatment for cardiac atherosclerotic events

Praluent (alirocumab) (by Sanofi Aventis), Approved July 2015
For the treatment of heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease

Athlete's Foot (Tinea Pedis)

Lamisil (terbinafine hydrochloride) Solution, 1% (by Novartis), Approved March 2000
For the treatment of athlete's foot, jock itch and ringworm

Lotrisone (clotrimazole/betamethasone diproprionate) lotion (by Schering-Plough), Approved December 2000
For the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis

Mentax (1% butenafine HCl cream) (by Penederm), Approved December 1997
Treatment for athlete's foot

Atopic Dermatitis

Desonate (desonide) (by Dow Pharm), Approved October 2006
For the treatment of atopic dermatitis

Dupixent (dupilumab) (by Regeneron Pharmaceuticals), Approved March 2017
For the treatment of atopic dermatitis

Elidel (by Novartis), Approved December 2001
Topical cream for the treatment of atopic dermatitis

Eucrisa (crisaborole) ointment (by Pfizer), Approved December 2016
For the treatment of atopic dermatitis

Protopic (tacrolimus) ointment (by Fujisawa Healthcare), Approved December 2000
For short-term and intermittent long-term treatment of moderate to severe atopic dermatitis

Verdeso (desonide) (by Connetics Corporation), Approved September 2006
For the treatment of atopic dermatitis

Atrial Fibrillation

Cardizem (R) (Diltiazem HC1 for injection) Monvial (R) (by Hoechst Marion Roussel), Approved September 1997
Delivery system for Monovial

Corvert Injection (ibutilide fumarate injection) (by Pharmacia & Upjohn), Approved December 1995
Treatment for irregular contractions of the heart

Eliquis (apixaban) (by Bristol-Myers Squibb), Approved December 2012
For the prevention of stroke and systemic embolism resulting from nonvalvular atrial fibrillation

Multaq (dronedarone) (by Sanofi-aventis), Approved July 2009
For the treatment of paroxysmal or persistent atrial fibrillation or atrial flutter

Pradaxa (dabigatran etexilate mesylate) (by Boehringer Ingelheim), Approved October 2010
For the risk reduction of stroke and embolism due to atrial fibrillation

Rythmol (by Knoll Pharmaceutical), Approved January 1998
Treatment for paroxysmal atrial fibrillation

Savaysa (edoxaban) (by Daiichi Sankyo), Approved January 2015
For the treatment of deep vein thrombosis, pulmonary embolism and risk of stroke and embolism due to atrial fibrillation

Tikosyn Capsules (by Pfizer), Approved October 1999
Capsules of dofetilide

Xarelto (rivaroxaban) (by Bayer), Approved July 2011
For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery

Xarelto (rivaroxaban) (by Janssen Pharmaceuticals), Approved November 2011
For the reduction in the risk of stroke and systemic embolism resulting from atrial fibrillation

Attention Deficit/Hyperactivity Disorder (ADHD - Adults)

Quillivant XR (methylphenidate hydrochloride) (by NextWave Pharmaceuticals), Approved September 2012
For the treatment of Attention Deficit Hyperactivity Disorder

Attention Deficit/Hyperactivity Disorder (ADHD - Pediatric)

Adderall (mixed salts of a single-entity amphetamine) (by Richwood Pharmaceutical), Supplemental NDA Approved February 1996
Treatment for attention-deficit/hyperactivity disorder

Adderall XR (by Shire Pharmaceuticals), Approved October 2001
Once-daily medication for the treatment of attention deficit/hyperactivity disorder (ADHD)

Concerta (by Alza), Approved August 2000
For the treatment of Attention Deficit Hyperactivity Disorder

Focalin (dexmethylphenidate HCl) (by Celgene), Approved November 2001
For the treatment of attention deficit hyperactivity disorder (ADHD)

Intuniv (guanfacine extended-release) (by Shire Pharmaceuticals), Approved September 2009
For the treatment of ADHD in children and adolescents

Kapvay (clonidine hydrochloride) (by Shionogi), Approved October 2010
For the treatment of attention deficit hyperactivity disorder

Metadate CD (by Celltech Pharmaceuticals), Approved April 2001
Oral capsules for the treatment of attention deficit hyperactivity disorder

Ritalin LA (methylphenidate HCl) (by Novartis), Approved June 2002
Oral capsules for the treatment Attention-Deficit/Hyperactivity Disorder (ADHD)

Strattera (atomoxetine HCl) (by Eli Lilly), December 2002
For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents and adults.

Vyvanse (Lisdexamfetamine Dimesylate) (by New River), Approved February 2007
For the treatment of Attention-Deficit/Hyperactivity Disorder

---------------------------------------------------------------------------------

[ Home | Discussions | Article Archives | Help | Submit your Site]

Copyright 1996 - 2014 by Gelber Associates All Rights Reserved.